SPONSOR
BioNTech SE
Total Trials
2
Recruiting
2
Phases
Phase 4, Phase 2
BioNTech SE is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including COVID-19 Vaccines, Non-small Cell Lung Cancer.
The trial portfolio spans Phase 4, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — BioNTech SE
How many clinical trials has BioNTech SE sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by BioNTech SE, of which 2 are actively recruiting participants. These trials cover conditions including COVID-19 Vaccines, Non-small Cell Lung Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does BioNTech SE research focus on?
BioNTech SE clinical trials span COVID-19 Vaccines, Non-small Cell Lung Cancer. The research pipeline includes Phase 4, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a BioNTech SE clinical trial?
To participate in a BioNTech SE trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all BioNTech SE trials with current recruitment status updated daily.
Clinical Trials by BioNTech SE
NCT07730450 Phase 4
Recruiting
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
COVID-19 Vaccines
NCT06841055 Phase 2
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Non-small Cell Lung Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology